GSK Spies Pfizer Challenge With $2.1bn Vaccine Company Acquisition

First Vaccine M&A Deal For Departing Barron

 
• By Andrew McConaghie
  
GSK vaccines
GSK has a blockbuster in Shingrix, but needs to invest more widely to retain its leading status in vaccines. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip